摘要
Abstract
Objective To investigate the effect of bevacizumab combined with chemotherapy on serum lev-els of tumor markers in patients with colorectal cancer(CRC).Methods A total of 72 CRC patients admit-ted to our hospital from June 2020 to June 2023 were selected and divided into an observation group and a con-trol group using the random number table method,with 36 cases in each group.The control group was treated with oxaliplatin combined with capecitabine chemotherapy,while the observation group was treated with bevaci-zumab on the basis of the control group's regimen.The short-term efficacy,serum levels of carbohydrate anti-gen(CA)199,CA125 and carcinoembryonic antigen(CEA),Karnofsky Performance Status(KPS)score and safety were compared between the two groups.Results After treatment,the short-term efficacy of the observation group was superior to that of the control group(P<0.05),the KPS score was higher than that of the control group(P<0.05),and the levels of CA199,CA125 and CEA were lower than those of the control group(P<0.05).Conclusion Bevacizumab combined with chemotherapy has a definite therapeutic effect in CRC patients,which can improve serum levels of tumor markers and enhance patients'quality of life without increasing toxic and side effects,thus being worthy of clinical promotion and application.关键词
结直肠癌/贝伐珠单抗/化疗/血清肿瘤标志物/疗效Key words
Colorectal cancer/Bevacizumab/Chemotherapy/Serum tumor markers/Therapeutic efficacy
